Literature DB >> 23289688

Handling worker and third-party exposures to nanotherapeutics during clinical trials.

Gurumurthy Ramachandran1, John Howard, Andrew Maynard, Martin Philbert.   

Abstract

The article focuses on issues relating to occupational exposures of researchers and lab workers, and exposures of bystanders such as health care workers and family members during HSR using nanomaterials. Such third-party exposures give rise to unique challenges relating to oversight as well as exposures to worker groups not previously studied. Given the current state of knowledge regarding health risks from such exposures, a more precautionary approach to oversight seems advisable.
© 2012 American Society of Law, Medicine & Ethics, Inc.

Mesh：

Year:  2012        PMID： 23289688     DOI： 10.1111/j.1748-720X.2012.00714.x

Source DB:  PubMed          Journal:  J Law Med Ethics        ISSN： 1073-1105            Impact factor:   1.718


  4 in total

1.  Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter?

Authors:  Priya Satalkar; Bernice Simone Elger; David M Shaw
Journal:  Sci Eng Ethics       Date:  2015-09-15       Impact factor: 3.525

2.  Rethinking risk assessment for emerging technology first-in-human trials.

Authors:  Anna Genske; Sabrina Engel-Glatter
Journal:  Med Health Care Philos       Date:  2016-03

Review 3.  Potential applications and human biosafety of nanomaterials used in nanomedicine.

Authors:  Hong Su; Yafei Wang; Yuanliang Gu; Linda Bowman; Jinshun Zhao; Min Ding
Journal:  J Appl Toxicol       Date:  2017-06-06       Impact factor: 3.446

Review 4.  Risk Assessment and Risk Minimization in Nanomedicine: A Need for Predictive, Alternative, and 3Rs Strategies.

Authors:  Lisa Accomasso; Caterina Cristallini; Claudia Giachino
Journal:  Front Pharmacol       Date:  2018-03-13       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.